News

RedHill Biopharma commenced advanced clinical trial with RHB-103 (migraine)

RedHill Biopharma commenced advanced clinical trial with RHB-103 (Migraine) (April 24 2012) English   RedHill Biopharma commenced advanced clinical trial with RHB-103 (Migraine) (April 24 2012) Hebrew

Read More...

RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-102 (prevention of nausea and vomiting)

RedHill announces successful pivotal BE trial results with RHB-102 (nausea and vomiting) – April 17, 2012 RedHill announces successful pivotal BE trial results with RHB-102 (nausea and vomiting) – Hebrew – April 17, 2012 See Dror Ben Asher (CEO) and Gilead Raday’s (VP Product Development) TV interview regarding RHB-102 trial results (Hebrew): http://www.bizportal.co.il/shukhahon/biznews02.shtml?mid=315186&strsrh=רדהיל    

Read More...

RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) featured by the Israeli Ministry of Foreign Affairs

http://www.mfa.gov.il/MFA/InnovativeIsrael/No-more-nausea-after-chemo-1-Mar-2012

Read More...

RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began

RedHill Biopharma commences advanced clinical trial with RHB-102 (Nausea and Vomiting) (February 14 2012) RedHill Biopharma commenced advanced clincial trial with RHB-102 (Nausea and Vomiting) (February 14 2012) Hebrew

Read More...

RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (prevention of nausea and vomiting)

RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 (Hebrew)

Read More...

RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting)

RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) Hebrew

Read More...

Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients)

See Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients): http://israel21c.org/health/daily-pill-to-vanquish-nausea-after-chemo

Read More...

IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial

IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial

Read More...

Dr. Jeff Lehighton presents RedHill Biopharma on Bloomberg TV

Please use the link below to watch Dr. Jeff Lehighton, RedHill Biopharma’s Chairman of the Advisory Board, on Bloomberg TV: http://www.bloomberg.com/video/80653140/

Read More...

RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients)

RedHill engages with CRO for potential pivotal trial with RHB-102 (Prevention of Nausea Vomiting ) (Hebrew) RedHill engages with CRO in preparation for potential pivotal trial with RHB-102 (prevention of nausea & vomiting )

Read More...

News